Lirum Therapeutics
New York, US · Founded 2021 · Delaware corporation
Find your way into Lirum Therapeutics
Lirum Therapeutics is a biopharmaceutical company that acquires, develops, and commercializes novel drug candidates for the treatment of difficult-to-treat, debilitating diseases. It was created by the former management team of Stemline Therapeutics.
Founders & leadership
DH
Daniel HumeNamed on SEC filing
KH
Kenneth HobermanNamed on SEC filing
MS
Mark SardNamed on SEC filing
IB
Ivan BergsteinChairman of the Board
Reported raises · per SEC filings
Form D private placements$6.3M disclosed across 1 round · 2023
▶$6.3MraisedFeb 2023 · 53 investors · BiotechnologyRule 506(b)
▶$6.3MraisedFeb 2023 · 53 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel HumeDirector
- Kenneth HobermanExecutive Officer, Director
- Mark SardDirector
- Ivan BergsteinDirector
- Offering amount
- $10M
- Amount sold
- $6.3M
- Minimum investment
- $5K
- Sales commissions
- $359.2K
- Placement agents
- ThinkEquity LLC
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Mirum Pharmaceuticals8 shared keywordsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.
Luminary Therapeutics6 shared keywordsLuminary Therapeutics is a clinical-stage biotech developing allogeneic CAR-T cell therapies built on its Gamma 2.0+ platform to treat solid tumors, B-cell malignancies, and B-cell-mediated autoimmune diseases. The company uses a Dual CAR architecture and the TcBuster transposon system to address relapse, T cell exhaustion, and high manufacturing costs.
Eli Lilly6 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Alumis5 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Relay5 shared keywordsRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
Companies competing with Lirum Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Lirum Therapeutics do?
- Lirum Therapeutics is a biopharmaceutical company that acquires, develops, and commercializes novel drug candidates for the treatment of difficult-to-treat, debilitating diseases. It was created by the former management team of Stemline Therapeutics.
- How much funding has Lirum Therapeutics raised?
- Lirum Therapeutics has disclosed $6.3M raised across 1 round.
- Where is Lirum Therapeutics headquartered?
- Lirum Therapeutics is headquartered in New York, US.